Citadel Advisors’s Akebia Therapeutics AKBA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $220K | Sell |
158,100
-53,600
| -25% | -$73.7K | ﹤0.01% | 11221 |
|
|
2025
Q4 | $341K | Sell |
211,700
-18,500
| -8% | -$38.7K | ﹤0.01% | 9863 |
|
|
2025
Q3 | $628K | Buy |
230,200
+46,500
| +25% | +$155K | ﹤0.01% | 8580 |
|
|
2025
Q2 | $669K | Buy |
183,700
+35,000
| +24% | +$96.2K | ﹤0.01% | 7947 |
|
|
2025
Q1 | $286K | Buy |
148,700
+58,900
| +66% | +$120K | ﹤0.01% | 9717 |
|
|
2024
Q4 | $171K | Buy |
89,800
+18,600
| +26% | +$32.3K | ﹤0.01% | 10690 |
|
|
2024
Q3 | $94K | Sell |
71,200
-6,300
| -8% | -$8.41K | ﹤0.01% | 11203 |
|
|
2024
Q2 | $79K | Sell |
77,500
-128,600
| -62% | -$159K | ﹤0.01% | 11226 |
|
|
2024
Q1 | $377K | Buy |
206,100
+100,000
| +94% | +$160K | ﹤0.01% | 8976 |
|
|
2023
Q4 | $132K | Buy |
106,100
+52,900
| +99% | +$54K | ﹤0.01% | 10588 |
|
|
2023
Q3 | $60.6K | Buy |
53,200
+15,300
| +40% | +$19.7K | ﹤0.01% | 11515 |
|
|
2023
Q2 | $34.7K | Buy |
37,900
+200
| +0.5% | +$193 | ﹤0.01% | 12204 |
|
|
2023
Q1 | $21.1K | Buy |
37,700
+18,700
| +98% | +$14.3K | ﹤0.01% | 13033 |
|
|
2022
Q4 | $11K | Sell |
19,000
-13,500
| -42% | -$4.23K | ﹤0.01% | 13593 |
|
|
2022
Q3 | $10K | Buy |
32,500
+6,400
| +25% | +$2.51K | ﹤0.01% | 12272 |
|
|
2022
Q2 | $9K | Sell |
26,100
-132,700
| -84% | -$55.7K | ﹤0.01% | 12601 |
|
|
2022
Q1 | $114K | Buy |
158,800
+79,700
| +101% | +$171K | ﹤0.01% | 12142 |
|
|
2021
Q4 | $179K | Sell |
79,100
-46,000
| -37% | -$125K | ﹤0.01% | 12011 |
|
|
2021
Q3 | $360K | Sell |
125,100
-87,600
| -41% | -$250K | ﹤0.01% | 10652 |
|
|
2021
Q2 | $806K | Buy |
212,700
+80,800
| +61% | +$272K | ﹤0.01% | 8922 |
|
|
2021
Q1 | $446K | Buy |
131,900
+15,100
| +13% | +$54.4K | ﹤0.01% | 9928 |
|
|
2020
Q4 | $327K | Sell |
116,800
-48,800
| -29% | -$142K | ﹤0.01% | 8922 |
|
|
2020
Q3 | $416K | Buy |
165,600
+151,500
| +1,074% | +$1.33M | ﹤0.01% | 7597 |
|
|
2020
Q2 | $191K | Sell |
14,100
-15,300
| -52% | -$158K | ﹤0.01% | 8566 |
|
|
2020
Q1 | $223K | Sell |
29,400
-4,200
| -13% | -$32.7K | ﹤0.01% | 7831 |
|
|
2019
Q4 | $212K | Buy |
+33,600
| New | +$160K | ﹤0.01% | 8081 |
|
|
2018
Q4 | – | Sell |
-17,000
| Closed | -$150K | – | 9030 |
|
|
2018
Q3 | $150K | Sell |
17,000
-4,400
| -21% | -$39.4K | ﹤0.01% | 8393 |
|
|
2018
Q2 | $214K | Buy |
+21,400
| New | +$214K | ﹤0.01% | 7776 |
|
|
2016
Q3 | – | Sell |
-17,800
| Closed | -$133K | – | 7183 |
|
|
2016
Q2 | $133K | Buy |
17,800
+6,000
| +51% | +$52.4K | ﹤0.01% | 6067 |
|
|
2016
Q1 | $106K | Buy |
+11,800
| New | +$95.7K | ﹤0.01% | 6002 |
|
|
2015
Q4 | – | Sell |
-5,500
| Closed | -$53K | – | 8680 |
|
|
2015
Q3 | $53K | Buy |
5,500
+3,400
| +162% | +$31.2K | ﹤0.01% | 7537 |
|
|
2015
Q2 | $22K | Buy |
+2,100
| New | +$17.9K | ﹤0.01% | 8099 |
|
Other funds holding AKBA
VCM
VPM
Citadel Advisors's AKBA Position: Q1 2026 in Review
Citadel Advisors reduced its Akebia Therapeutics (AKBA) stake by 70% in Q1 2026, selling an estimated $4.5M and leaving 1,390,067 shares worth $1.93M. The position accounts for ﹤0.01% of the portfolio, ranked #6131.
Citadel Advisors first reported a position in AKBA in Q1 2014 and has held it in 38 quarters since. The position peaked at $8.76M in Q3 2018. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.
- Citadel Advisors held 1,390,067 shares of Akebia Therapeutics worth $1.93M as of Q1 2026.
- Citadel Advisors sold 3,275,470 Akebia Therapeutics shares in Q1 2026, an estimated $4.5M.
- Akebia Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6131 holding.
- Citadel Advisors first reported a position in Akebia Therapeutics in Q1 2014 and has held it in 38 quarters since.
- Citadel Advisors's Akebia Therapeutics position peaked at $8.76M in Q3 2018.
- 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.